Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access
This article was originally published in The Pink Sheet Daily
Executive Summary
Witnesses call for political pressure on FDA to approve the Duchenne drug; patients and advocates also urge general approval reciprocity with Europe and incentives for pediatric trials; agency was not invited to testify.